A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

Vijay K. Singha Department of Pharmacology and Molecular Therapeutics, Division of Radioprotectants, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA;b Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USACorrespondence[email protected]

https://orcid.org/0000-0002-6631-3849 View further author information

Oluseyi O. Fatanmia Department of Pharmacology and Molecular Therapeutics, Division of Radioprotectants, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA;b Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Stephen Y. Wisea Department of Pharmacology and Molecular Therapeutics, Division of Radioprotectants, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA;b Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Alana Carpentera Department of Pharmacology and Molecular Therapeutics, Division of Radioprotectants, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA;b Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Sara Nakamura-Peeka Department of Pharmacology and Molecular Therapeutics, Division of Radioprotectants, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA;b Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USAView further author information

Artur A. Serebrenikc Humanetics Corporation, Edina, MN, USAView further author information

Michael D. Kaytorc Humanetics Corporation, Edina, MN, USAView further author information

show all

A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A novel oral formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date